NCT00899405Recruiting

Studying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung Cancer

EGFR Pathway Mutations in Lung Cancer Patient Tumors and Blood

Source: ClinicalTrials.gov · Last updated 25 Jun 2026

Brief summary (registry, in English)

RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is looking at tumor tissue samples and blood samples to learn more about DNA changes in patients with lung cancer.

Status (registry): Recruiting
Study type: Observational
Enrollment: 800 (estimated)
First submitted: 9 May 2009
Start date: 19 May 2004
Primary completion date: 31 May 2034
Lead sponsor: University of California, Davis
Diseases: Lung cancer
NCT number: NCT00899405

What you commit to

Study type: Observational
Planned participants: 800
From 19 May 2004 to the primary completion date, 31 May 2034
1 site in 1 country
Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Criteria the registry did not label

DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed lung cancer
- PATIENT CHARACTERISTICS:
Not specified
- PRIOR CONCURRENT THERAPY:
May have received prior EGFR inhibitors

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

Site	City	Country	Site status
University of California Davis Cancer Center Coordinator of this site? Confirm its status	Sacramento	United States	Recruiting

This page is information, not medical advice. Discuss any trial with your doctor.